The Changing Market Pattern of the Pharmaceutical Industry
Abstract: China's pharmaceutical industry has entered a new era, and the future 5 to 10 years is the key period for the development of medicine.
On November 24, 2017, the “2017 China Medical Capital Forum” was grandly opened in Chengdu. More than 20 capital owners, industry leaders and the elites of more than 50 pharmaceutical listed companies and more than 10 investment and investment institutions from all over the country shared the annual feast of the pharmaceutical industry.
Guo Yunpei, President of China Pharmaceutical Enterprise Management Association, attended the forum and delivered a speech. He mentioned that China is now in an important period of becoming a powerful pharmaceutical country. However, the current situation of China's biomedical industry with small, scattered and chaotic conditions has not yet been fundamentally changed.
With the changes in the pharmaceutical industry structure, it is predicted that in the next year there will be a major reshuffle of a large-scale industry. By five years after the closure of the merger and transfer, the total number of Chinese biomedical enterprises will be reduced by a quarter. Besides, the development of China's pharmaceutical listed companies is not balanced, and the governance of listed companies needs to be improved. Therefore, improving the operation quality of pharmaceutical listed companies is a lesson to be developed in the healthy development of biomedicine industry.
Tao Jianhong, Deputy Director of the State Administration of Food and Drug Administration's Southern Medical Economics Institute, said that when the healthy China is expected to reach its goal in 2020, the total scale of China's large-scale health industry will reach 8% of GDP and the total amount will exceed 7.2 trillion Yuan. The total scale will be 2.5 times larger.
In recent years, various policies have strongly promoted the development of the pharmaceutical industry, especially innovative drugs, which also stimulates the development of related industries, such as the pharmaceutical machinery. Tao Jianhong believes that China will usher in a second wave of imported drugs in the future. Under the background of the "two-vote system", the circulation pattern will be changed. The pharmaceutical circulation industry will usher in the reshuffle, and the industry consolidation will speed up. Fields of elder and children care and special medical food will be the future opportunities for the industry.
Eddited by KOSBEST